Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1405 in Chinese Patients With Advanced Solid Tumors
CTR20181522Phase 2Terminated
- Sponsor
- Zhixiang Jintai
- Start
- Nov 2019
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GR-1405 in Nonhematologic neoplasms, nasopharyngeal carcinoma (NPC), head and neck squamous cell carcinoma (HNSCC), sponsored by Zhixiang Jintai. Started Nov 2019; status: terminated.
02
Drugs
GR-1405
03
Conditions
Nonhematologic neoplasmsnasopharyngeal carcinoma (NPC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20181522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181522.